{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:09:36Z","timestamp":1777576176999,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The objective of this study was to develop a predictive nomogram for intermediate-risk differentiated thyroid cancer (DTC) patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation (RRA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 265 patients who underwent total thyroidectomy with central lymph node dissection (CND) and received RRA treatment at a single institution between January 2018 and March 2023 were analyzed. Patients with certain exclusion criteria were excluded. Univariate and multivariate logistic regression analyses were performed to identify risk factors for a non-excellent response (non-ER) to RRA. A nomogram was developed based on the risk factors, and its performance was validated using the Bootstrap method with 1,000 resamplings. A web-based dynamic calculator was developed for convenient application of the nomogram.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 265 patients with intermediate-risk DTC. Significant differences were found between the ER group and the non-ER group in terms of CLNM&amp;gt;5, Hashimoto\u2019s thyroiditis, sTg level, TgAb level (P &amp;lt; 0.05). CLNM&amp;gt;5 and sTg level were identified as independent risk factors for non-ER in multivariate analysis. The nomogram showed high accuracy, with an area under the curve (AUC) of 0.833 (95% CI = 0.770\u20130.895). The nomogram\u2019s predicted probabilities aligned closely with actual clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study developed a predictive nomogram for intermediate-risk DTC patients after fixed 3.7GBq (100mCi) RRA. The nomogram incorporates CLNM&amp;gt;5 and sTg levels as risk factors for a non-ER response to RRA. The nomogram and web-based calculator can assist in treatment decision-making and improve the precision of prognosis information. Further research and validation are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1361683","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T05:55:33Z","timestamp":1717048533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation"],"prefix":"10.3389","volume":"15","author":[{"given":"Lu","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinquan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(71)81043-7","article-title":"Radioiodine therapy of thyroid cancer","volume":"1","author":"Eric Pochin","year":"1971","journal-title":"Semin Nucl Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/jc.2006-1345","article-title":"131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review","volume":"92","author":"Hackshaw","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2021.0288","article-title":"Radioiodine remnant ablation for differentiated thyroid cancer: A systematic review and meta-analysis","volume":"147","author":"James","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243642","article-title":"Unexplained hyperthyroglobulinemia in differentiated thyroid cancer patients as an indication for radioiodine adjuvant therapy: A prospective multicenter study","volume":"62","author":"Cheng","year":"2021","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.994288","article-title":"Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration","volume":"13","author":"Sun","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0597","article-title":"Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A joint statement from the american thyroid association, the european association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the european thyroid association","volume":"29","author":"Tuttle","year":"2019","journal-title":"Thyroid"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.beem.2022.101703","article-title":"Radioiodine therapy in the different stages of differentiated thyroid cancer","volume":"37","author":"Valerio","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.035535","article-title":"Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer","volume":"48","author":"Handkiewicz-Junak","year":"2007","journal-title":"J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00640","article-title":"Efficacy and affecting factors of 131I thyroid remnant ablation after surgical treatment of differentiated thyroid carcinoma","volume":"8","author":"Wang","year":"2018","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000489849","article-title":"Prognostic value of stimulated thyroglobulin levels at the time of radioiodine administration in differentiated thyroid cancer","volume":"7","author":"Spaas","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.029","article-title":"Anatomic features of enhancing renal masses predict Malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score","volume":"60","author":"Kutikov","year":"2011","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy","volume":"31","author":"Wang","year":"2013","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.030","article-title":"Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay","volume":"63","author":"Hansen","year":"2013","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.1290","article-title":"Are nomograms better than currently available stage groupings for bladder cancer","volume":"24","author":"Sternberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007512","article-title":"Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer","volume":"96","author":"Ha","year":"2017","journal-title":"Medicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-017-1190-3","article-title":"Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy","volume":"31","author":"Park","year":"2017","journal-title":"Ann Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab445","article-title":"Prognostic implications of preablation stimulated Tg: A retrospective analysis of 2500 thyroid cancer patients","volume":"106","author":"Tian","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000636","article-title":"Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer","volume":"38","author":"Jeong","year":"2017","journal-title":"Nucl Med Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12149-019-01357-6","article-title":"Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer","volume":"33","author":"Iizuka","year":"2019","journal-title":"Ann Nucl Med"},{"key":"B21","article-title":"Factors affecting ablation success after I-131 radioactive iodine therapy in low and intermediate risk papillary thyroid cancer","volume":"55","author":"Goksel","year":"2023","journal-title":"Horm Metab Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac745","article-title":"Response to surgery assessments for sparing radioiodine remnant ablation in intermediate-risk papillary thyroid cancer","volume":"108","author":"Zhang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad171","article-title":"Adjuvant radioiodine for intermediate-risk papillary thyroid cancer-to treat or not to treat","volume":"108","author":"van Velsen","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15593258211062775","DOI":"10.1177\/15593258211062775","article-title":"Comparing high and low-dose radio-iodine therapy in thyroid remnant ablation among intermediate and low-risk papillary thyroid carcinoma patients-single centre experience","volume":"19","author":"Yasmin","year":"2021","journal-title":"Dose Response"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4288","article-title":"Lymph node metastases >5 and metastatic lymph node ratio >0.30 of differentiated thyroid cancer predict response to radioactive iodine","volume":"10","author":"Yun","year":"2021","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12893-022-01635-7","article-title":"Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma","volume":"22","author":"Zhan","year":"2022","journal-title":"BMC Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40618-022-01949-6","article-title":"A nomogram and risk classification system for predicting cancer-specific survival in tall cell variant of papillary thyroid cancer: a SEER-based study","volume":"46","author":"Wang","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05302-z","article-title":"Development and validation of a nomogram for predicting the early death of anaplastic thyroid cancer: a SEER population-based study","volume":"149","author":"Cui","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13665","article-title":"Development and validation of a nomogram to predict cancer-specific survival in middle-aged patients with papillary thyroid cancer: A SEER database study","volume":"9","author":"Tang","year":"2023","journal-title":"Heliyon"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.800639","article-title":"Nomogram individually predicts the risk for distant metastasis and prognosis value in female differentiated thyroid cancer patients: A SEER-based study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882279","article-title":"Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: A SEER database analysis","volume":"13","author":"Jin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02129-wp","article-title":"Development and validation of survival nomograms for patients with differentiated thyroid cancer with distant metastases: a SEER Program-based study","author":"Ma","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.743310","article-title":"Delayed initial radioiodine adjuvant therapy does affect biochemical response in intermediate- to high-risk differentiated thyroid cancer","volume":"12","author":"Yu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1361683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T05:56:01Z","timestamp":1717048561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1361683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":33,"alternative-id":["10.3389\/fendo.2024.1361683"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1361683","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1361683"}}